Targets › LMP1
3 programs from 2 companies in 5 trials: 5 Phase 1; Oncology, Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on LMP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Baylor College of Medicine | EBV-specific T cells: A (LMP, BARF1 and EBNA1 specific CTLs) EBV-specific cytotoxic T lymphocytes targeting viral antigens LMP1, LMP2, BARF1, and EBNA1 | LMP1, LMP2, BARF1, EBNA1 | Phase 1 | Hodgkin's Disease | Mar 2027 |
| ModernaTX | mRNA-1189 mRNA vaccine encoding Epstein-Barr virus antigens | EBNA1, LMP1, BZLF1 | Phase 1 | Epstein-Barr Virus Infection; Epstein-Barr Virus | May 2027 |
| Baylor College of Medicine | MABEL CTLs EBV-specific cytotoxic T lymphocytes targeting LMP, BARF-1 and EBNA1 viral antigens | LMP1, BARF1, EBNA1 | Phase 1 | Hodgkin Disease | Mar 2029 |
Epstein-Barr Virus Infection (2) Epstein-Barr Virus (1) Hodgkin Disease (1) Hodgkin's Disease (1)
other (2), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.